Century Therapeutics shares fall 1.82% after-hours as patient dosing continues in CALiPSO-1 trial.

Century Therapeutics, Inc. declined 1.82% in after-hours trading. The company reported ongoing patient dosing in the CALiPSO-1 trial and is on track to report clinical data for CNTY-101 by year-end 2025. Additionally, CNTY-308, a CAR-iT cell therapy, is in IND-enabling studies as a potential treatment for B-cell-mediated diseases, with plans to progress into the clinic in 2026. Dr. Brent Pfeiffenberger, CEO, was appointed to Board Chair, and the company's cash runway was extended into the fourth quarter of 2027.